Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRT1419 · 2 trials · 11 indications
Dose limiting toxicities will be evaluated through the first cycle
The MTD and/or OBD will be established for further investigation in participants with advanced solid tumors.
The RP2D will be established for further investigation in participants with advanced solid tumors.
Dose limiting toxicities will be evaluated through the first cycle
The MTD and/or OBD will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
The RP2D will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
| Arm | Type | Description |
|---|---|---|
| PRT1419 | EXPERIMENTAL | PRT1419 will be administered by intravenous infusion |
| Name | Type | Description |
|---|---|---|
| PRT1419 | DRUG | PRT1419 will be administered by intravenous infusion |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Adequate organ function (bone marrow, hepatic, renal, cardiovascular) * Left ventricular ejection fraction of ≥ 50% * Female patients of childbearing potential must have a negative pregnancy test within 7 da...
Top 20 of 24 competitors
PRT1419 is an investigational small molecule being studied in oncology for advanced solid tumors, including sarcoma, and for relapsed or refractory hematologic malignancies such as multiple myeloma. It is not approved for any indication and remains in clinical development.
PRT1419 targets MCL-1, a protein in the BCL-2 family that regulates apoptosis. By inhibiting MCL-1, PRT1419 is designed to promote programmed cell death in cancer cells that depend on this protein for survival.
PRT1419 is being developed by Prelude Therapeutics Incorporated, which trades on the Nasdaq under the ticker PRLD. The company is the sponsor of the clinical studies evaluating the compound.
PRT1419 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication.
PRT1419 has been evaluated in two completed Phase 1 trials: NCT04837677 in advanced solid tumors including sarcoma, and NCT04543305 in relapsed or refractory hematologic malignancies including multiple myeloma. Both studies were conducted in the United States.